Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07577804 HSK-31858 Bronchiectasis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07577804 clinical trial report covering HSK-31858, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07578116 Trastuzumab Oligometastatic Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07578116 clinical trial report covering Trastuzumab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
6 min read
Brolucizumab Biologics Sequence Review Report 2026: VEGF-A Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Brolucizumab, an antibody fragment targeting VEGF-A.
Latest Hotspot
8 min read
NCT07579234 Recombinant humanized anti-BCMA/CD3 bispecific antibody(Shandong New Time Pharma Refractory Multiple Myeloma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07579234 clinical trial report covering Recombinant humanized anti-BCMA/CD3 bispecific antibody(Shandong New Time Pharma, Phase 3, endpoints, sponsor, geog
Latest Hotspot
8 min read
NCT07582432 Immune Globulin (Human)(Grifols) Secondary Antibody Deficiency Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07582432 clinical trial report covering Immune Globulin (Human)(Grifols), Phase 3, endpoints, sponsor, geography, readout timing and development white spac
6 min read
Ranibizumab Biologics Sequence Review Report 2026: VEGF-A Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ranibizumab, an antibody fragment targeting VEGF-A.
Latest Hotspot
8 min read
JPRN-jRCT2071260025 Cenobamate Epilepsies, Partial Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
JPRN-jRCT2071260025 clinical trial report covering Cenobamate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07581951 HSK-31679 Metabolic Dysfunction Associated Steatohepatitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07581951 clinical trial report covering HSK-31679, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
6 min read
Bevacizumab Biologics Sequence Review Report 2026: VEGF-A Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Bevacizumab, an antibody targeting VEGF-A.
Latest Hotspot
8 min read
NCT07582315 Izalontamab Brengitecan Biliary Tract Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07582315 clinical trial report covering Izalontamab Brengitecan, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07579351 Dexamethasone Sodium Phosphate Radicular Pain Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07579351 clinical trial report covering Dexamethasone Sodium Phosphate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20261878 Recombinant Zoster Vaccine(CHO Cell)(Kangtai) Herpes Zoster Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
CTR20261878 clinical trial report covering Recombinant Zoster Vaccine(CHO Cell)(Kangtai), Phase 3, endpoints, sponsor, geography, readout timing and developme